Incyte market cap
WebApr 11, 2024 · Incyte Corp.'s market capitalization is $16.44 B by 222.96 M shares outstanding. Is Incyte stock a Buy, Sell or Hold? Incyte stock has received a consensus … WebIncyte Corporation (INCY) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 74.17 +0.24 (+0.32%) At close: 04:00PM EDT. 74.17 0.00 (0.00%) After …
Incyte market cap
Did you know?
WebIncyte Sep 2024 - Present2 years 8 months Wilmington, Delaware, United States Incyte Corporation (Nasdaq: INCY) Market Cap: ~$19 billion): At Incyte, our therapeutic focus spans Oncology... WebApr 12, 2024 · The company has a market cap of $16.54 billion, a P/E ratio of 48.80, a price-to-earnings-growth ratio of 3.28 and a beta of 0.73. Incyte ( NASDAQ:INCY - Get Rating) last released its quarterly earnings results on Tuesday, February 7th.
WebApr 11, 2024 · Exchange Traded Concepts LLC decreased its position in Incyte Co. (NASDAQ:INCY - Get Rating) by 7.5% during the 4th quarter, according to the company in its most recent filing with the SEC. ... The company has a market cap of $16.48 billion, a price-to-earnings ratio of 48.64, a PEG ratio of 3.28 and a beta of 0.73. The company has a … WebMarket Capitalization Definition Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric is …
WebMar 7, 2024 · Incyte has a collaboration agreement with Eli Lilly for Olumiant. The drug is a once-daily, oral JAK inhibitor discovered by Incyte and licensed to LLY. It is approved for several types of... WebApr 11, 2024 · Incyte Co. has a 1-year low of $65.07 and a 1-year high of $86.29. The company has a market cap of $16.48 billion, a price-to-earnings ratio of 48.64, a price-to-earnings-growth ratio of 3.28 and ...
WebMar 26, 2015 · Their market caps are within a 20% spread. The revenue spread is greater, with Pharmacyclics running over 2 times Incyte's revenue, but Incyte showed a better net loss than BioMarin. They all...
WebApr 12, 2024 · The firm has a market cap of $16.62 billion, a P/E ratio of 49.03, a PEG ratio of 3.28 and a beta of 0.73. The firm has a 50-day moving average price of $76.11 and a two-hundred day moving average price of $76.92. Incyte has a 52-week low of $65.07 and a 52-week high of $86.29. Gilead Sciences: Now is Not the Time to Get Sticker Shock earthbound original snes cartridgeWebMar 11, 2024 · Incyte's ruxolitinib, a type of non-steroidal anti-inflammatory medication called a JAK inhibitor, already makes up a major chunk of earnings, representing $2.22 … cteensummer.comWebApr 6, 2024 · INCY stock opened at $73.78 on Thursday. The company's 50 day moving average is $76.94 and its 200 day moving average is $76.65. The stock has a market cap of $16.45 billion, a price-to-earnings ratio of 48.54, a price-to-earnings-growth ratio of 3.14 and a … cteen shluchimWebApr 10, 2024 · INCY Complete Incyte Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. cte em inglesWebApr 10, 2024 · Market Cap $16.45B Shares Outstanding 222.97M Public Float 220.79M Beta 0.68 Rev. per Employee $1.461M P/E Ratio 49.62 EPS $1.52 Yield N/A Dividend N/A Ex-Dividend Date N/A Short Interest 6.53M... earthbound ost midiWebApr 10, 2024 · Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre … cteen promotional itemsWebApr 12, 2024 · The company has a market cap of $16.54 billion, a P/E ratio of 48.80, a price-to-earnings-growth ratio of 3.28 and a beta of 0.73. Incyte ( NASDAQ:INCY – Get Rating ) last released its quarterly ... cte energy services